Covidien appoints Bayer's Trudeau president of pharma
This article was originally published in Scrip
Executive Summary
Covidien has appointed Mark Trudeau president of its pharmaceuticals segment and a senior vice-president of the company, effective 1 February. With 25 years' experience of the pharmaceutical industry, Mr Trudeau is currently president and CEO of Bayer Healthcare. He has also served in various positions at Bristol-Myers Squibb, Abbott Laboratories and Lilly. Mr Trudeau succeeds Matthew Harbaugh who served as interim president since 2010 when Timothy Wright resigned, and will continue his role as CFO.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.